{"id":749065,"date":"2023-04-19T08:35:57","date_gmt":"2023-04-19T12:35:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/"},"modified":"2023-04-19T08:35:57","modified_gmt":"2023-04-19T12:35:57","slug":"xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/","title":{"rendered":"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

\n TNF is involved in the development of Alzheimer\u2019s\u00a0Disease\u00a0pathology following<\/em>\u00a0traumatic\u00a0brain\u00a0injury<\/em>\u00a0and\u00a0is prevented by neutralization of\u00a0soluble TNF\u00a0by XPRO\u2122<\/em><\/p>\n

Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) — \u00a0INmune Bio, Inc.<\/strong><\/a>\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announced pre-clinical data detailing research led by Kirsty J. Dixon of the Department of Surgery, Virginia Commonwealth University (VCU), and Elliott Mufson, Barrow Neurological Institute. In the pre-clinical study, Alzheimer\u2019s Disease related amyloid pathology increased after Traumatic Brain Injury (TBI) in an at-risk mouse model. Treatment with XPro\u2122 one hour after TBI prevents the development of amyloid pathology in the brain. These data show that soluble TNF drives the development of amyloid pathology after TBI, which can be prevented by neutralizing sTNF with XPro\u2122.<\/p>\n

\u201cThe unfortunate reality of TBI is that the acute injury often overshadows the long-term consequences, which includes the potential for later developing Alzheimer\u2019s disease,\u201d said Kirsty Dixon, Assoc. Prof. of Surgery at VCU. \u201cMy team that includes Ph.D. student Michelle Taylor, and MD\/Ph.D. student Chelsie Poffenberger investigate the role of soluble TNF in both the acute injury setting and chronically following TBI.\u00a0 We hope this research may determine the relationship between TBI and AD.\u201d\u00a0<\/p>\n

\u201cTBI remains a major health problem affecting more than\u00a050 million<\/u><\/a>\u00a0people worldwide per year,\u201d said RJ Tesi MD, CEO of INmune Bio, \u201cFew realize that the elderly have the\u00a0greatest risk of hospitalizations and death due to TBI<\/u><\/a>. The ability of XPro to prevent amyloid formation after head injury suggests early intervention may help to prevent the development of AD in the elderly with TBI.\u201d<\/p>\n

The Company provided XPro1595 to Kirsty Dixon and her research team through an MTA collaboration with VCU. The Company, and its research partners continue to investigate the involvement of soluble TNF and potential applications of XPro1595 for treating disease. The data was presented in a poster at the AD\/PD\u2122 2023 International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease in Gothenburg, Sweden on 1 April 2023.<\/p>\n

\n About\u00a0XPro1595<\/strong>\n <\/p>\n

XPro\u2122 is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro\u2122 could potentially have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation and restoring innate immune cell function. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit\u00a0this section of the INmune Bio\u2019s website<\/u><\/a>.<\/p>\n

\n About INmune Bio, Inc.<\/strong>\n <\/p>\n

\n
\n INmune<\/strong>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>
\n
\n Bio,<\/strong>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>
\n
\n Inc<\/strong>
\n <\/a>
\n
\n .<\/u>
\n <\/a>\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03\u2122), Early Alzheimer\u2019s disease, and treatment-resistant depression (XPro\u2122). The Natural Killer Cell Priming Platform includes INKmune\u2122 developed to prime a patient\u2019s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio\u2019s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit\u00a0www.inmunebio.com<\/strong><\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.\u00a0 Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03\u2122, XPro1595 (XPro\u2122), and INKmune\u2122 are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.<\/p>\n

\n INmune Bio<\/strong>\u00a0Contact:<\/strong>
David Moss, CFO (858) 964-3720
info@inmunebio.com<\/strong><\/a><\/p>\n

\n Investor<\/strong>\u00a0Contact:<\/strong>
Jason Nelson
Core IR
(516) 842-9614 x-823 <\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TNF is involved in the development of Alzheimer\u2019s\u00a0Disease\u00a0pathology following\u00a0traumatic\u00a0brain\u00a0injury\u00a0and\u00a0is prevented by neutralization of\u00a0soluble TNF\u00a0by XPRO\u2122 Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) — \u00a0INmune Bio, Inc.\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announced pre-clinical data detailing research led by Kirsty J. Dixon of the Department of Surgery, Virginia Commonwealth University (VCU), and Elliott Mufson, Barrow Neurological Institute. In the pre-clinical study, Alzheimer\u2019s Disease related amyloid pathology increased after Traumatic Brain Injury (TBI) in an at-risk mouse model. Treatment with XPro\u2122 one hour after TBI prevents the development of amyloid pathology in the brain. These data show that soluble TNF drives the development of amyloid … <\/p>\n

Continue reading “XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749065","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nXPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TNF is involved in the development of Alzheimer\u2019s\u00a0Disease\u00a0pathology following\u00a0traumatic\u00a0brain\u00a0injury\u00a0and\u00a0is prevented by neutralization of\u00a0soluble TNF\u00a0by XPRO\u2122 Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) — \u00a0INmune Bio, Inc.\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announced pre-clinical data detailing research led by Kirsty J. Dixon of the Department of Surgery, Virginia Commonwealth University (VCU), and Elliott Mufson, Barrow Neurological Institute. In the pre-clinical study, Alzheimer\u2019s Disease related amyloid pathology increased after Traumatic Brain Injury (TBI) in an at-risk mouse model. Treatment with XPro\u2122 one hour after TBI prevents the development of amyloid pathology in the brain. These data show that soluble TNF drives the development of amyloid … Continue reading "XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T12:35:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease\",\"datePublished\":\"2023-04-19T12:35:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/\"},\"wordCount\":964,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/\",\"name\":\"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==\",\"datePublished\":\"2023-04-19T12:35:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease - Market Newsdesk","og_description":"TNF is involved in the development of Alzheimer\u2019s\u00a0Disease\u00a0pathology following\u00a0traumatic\u00a0brain\u00a0injury\u00a0and\u00a0is prevented by neutralization of\u00a0soluble TNF\u00a0by XPRO\u2122 Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) — \u00a0INmune Bio, Inc.\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, announced pre-clinical data detailing research led by Kirsty J. Dixon of the Department of Surgery, Virginia Commonwealth University (VCU), and Elliott Mufson, Barrow Neurological Institute. In the pre-clinical study, Alzheimer\u2019s Disease related amyloid pathology increased after Traumatic Brain Injury (TBI) in an at-risk mouse model. Treatment with XPro\u2122 one hour after TBI prevents the development of amyloid pathology in the brain. These data show that soluble TNF drives the development of amyloid … Continue reading \"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-19T12:35:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease","datePublished":"2023-04-19T12:35:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/"},"wordCount":964,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/","name":"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==","datePublished":"2023-04-19T12:35:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDczMiM1NTM0MTk2IzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749065"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749065\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}